Alginate hydrogels offer mild ionic gelation and tunable porosity for drug delivery, yet their hydrophilic, macroporous networks suffer from rapid initial burst release of water-soluble payloads. Here we introduce a hierarchical barrier-engineering strategy in which poly(D,L-lactide-co-glycolide)/poly(ethylene glycol) (PLGA/PEG) blend coatings are applied via dip-coating to Ca2+-cross-linked alginate beads (~1 mm) and microgels (~100 µm). For beads, three-cycle PLGA/PEG multilayer coating suppressed the initial swelling rate (dQ/dt) by ~50% and reduced 1 h burst release from >85% to ~60%, functioning as an “early-burst buffer” rather than a long-term depot. For microgels, a single PLGA/PEG layer partially attenuated burst release; however, an additional PLGA outer shell (double-barrier architecture) shifted the release-governing mechanism from swelling-dominated to diffusion-barrier-dominated control, limiting 10 min release to 50% for beads, >20% for microgels) without compromising gel integrity. In beads, burst control was governed by swelling suppression; in microgels, the additional PLGA shell shifted control to diffusion-barrier-dominated release, demonstrating that barrier architecture must be adapted to particle scale.
9 July 2020 in Journal of Bioactive and Compatible Polymers
Poly lactic-co-glycolic acid particles are biodegradable and biocompatible drug delivery systems that provide a controlled release of drugs in specific sites. These characteristics minimize the occurrence of side effects related to overdosing. To overcome the issues associated with the conservative treatment for wound healing, the objective of this work was to develop a poly lactic-co-glycolic acid particles system to deliver anti-inflammatory compounds (epigallocatechin gallate and asiaticoside) to fibroblasts. Nanoscale (~200 nm) and microscale (~10 µm) poly lactic-co-glycolic acid particles were produced using two different protocols. Nanoscale particles reduced cell proliferation by 46% compared with untreated human skin fibroblasts, whereas microscale particles did not affect fibroblast viability significantly. The toxicity of nanoparticles and the nontoxic nature of microparticles were confirmed in live and dead cell staining experiments. In vitro drug release assays showed that particles containing epigallocatechin gallate and asiaticoside were able to release most of their payload during the first 8 h of incubation. The treatment of lipopolysaccharide-stimulated fibroblasts with epigallocatechin gallate- and asiaticoside-loaded microparticles effectively suppressed the expression of inflammatory factors: tumor necrosis factor-α, interleukin-1β, and interleukin-6. In this study, we found that the optimal size of biodegradable poly lactic-co-glycolic acid particles for the delivery of physiologically active substances to fibroblasts is about 10 μm. Moreover, our findings indicate that poly lactic-co-glycolic acid particles of this size can be effectively applied to ameliorate tissue regeneration by delivering physiologically active substances to improve skin lesion recovery.